InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.016 -0.019 (-54.29%)+
Announcement
Release
20 Jan 2026 9:31AM
Price at Release
$0.035
Full Release
download
Summary
Atomo Diagnostics Limited announced an exclusive global licensing agreement with the Burnet Diagnostics Initiative to commercialize a novel liver function test using its Pascal cassette. This test, which measures alanine aminotransferase (ALT) to detect liver inflammation, has a significant market potential for patients starting drug treatments with known liver injury risks. The licensing agreement includes royalties and milestone payments based on regulatory approvals in key markets. Initial applications focus on monitoring drug-induced liver injury, with plans to extend to other chronic liver conditions.
Key Points
  • Atomo Diagnostics Limited has secured an exclusive global licensing agreement with the Burnet Diagnostics Initiative for a novel liver function test.
  • The test measures alanine aminotransferase (ALT) to detect liver inflammation and damage.
  • Initial focus is on monitoring drug-induced liver injury (DILI) with product development nearly complete.
  • The market potential for the rapid test is significant, especially for patients starting treatments with known liver injury risks.
  • The agreement includes royalty payments to Burnet and milestone payments upon securing regulatory approvals in the US, Europe, and Australia.
  • Atomo will utilize its proven Pascal cassette for the delivery of the test.
  • Atomo's collaboration with Burnet also includes a project for a novel syphilis test under a federal government grant.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.